Pasithea Therapeutics Corp To Acquire AlloMek Therapeutics Transcript
Good morning. My name is Tiago Reis Marques, and I'm the CEO of Pasithea Therapeutics. It is with great pleasure that I'm here today announcing our latest acquisition, AlloMek Therapeutics, a preclinical biotech company.
First, we have our standard forward-looking statement. Please read them at your convenience. And also mentioning that joining me today on this webinar are Uday Khire, CEO of AlloMek; and Professor Howard Worman, Chairman of the Scientific Advisory Board of AlloMek; as well as Graeme Currie, Pasithea's Chief Development Officer; and Pasithea's Chairman, Professor Larry Steinman.
But first, let me guide you through the highlights of this acquisition. MEK 1/2 inhibitors are FDA-approved drugs for various indications with tremendous market opportunities. As an example, selumetinib was approved in 2020 for NF1 and achieved over $100 million in annual sales last year. AlloMek has developed what we consider a potential best-in-class MEK inhibitor, CIP-137401, with unique drug-like properties, reflects of its
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
